Stockscreener 앱 받기
291.97
0.05%
-0.15
시간 외 거래:
291.97
전일 마감가:
$292.12
열려 있는:
$293.63
하루 거래량:
1.39M
Relative Volume:
0.80
시가총액:
$55.74B
수익:
$303.19B
순이익/손실:
$1.40B
주가수익비율:
41.53
EPS:
7.03
순현금흐름:
$-638.10M
1주 성능:
+1.47%
1개월 성능:
+4.88%
6개월 성능:
+24.78%
1년 성능:
+30.37%
1일 변동 폭
$291.08
$294.20
1주일 범위
$285.42
$294.20
52주 변동 폭
$214.77
$296.65
Cencora Inc Stock (COR) Company Profile
명칭
Cencora Inc
전화
610-727-7000
주소
1 WEST FIRST AVENUE, CONSHOHOCKEN
COR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
291.97 | 55.74B | 303.19B | 1.40B | -638.10M | 7.03 |
|
MCK
Mckesson Corporation
|
707.00 | 85.53B | 344.58B | 2.83B | 1.63B | 21.84 |
|
CAH
Cardinal Health Inc
|
151.99 | 32.30B | 222.16B | 1.31B | -486.00M | 5.36 |
|
HSIC
Henry Schein Inc
|
66.58 | 8.03B | 12.50B | 314.00M | 421.00M | 2.44 |
|
AHG
Akso Health Group Adr
|
1.425 | 546.39M | 2.22M | -5.63M | -1.68M | -0.24 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-04 | 재개 | Mizuho | Outperform |
| 2024-09-18 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-02-26 | 개시 | Leerink Partners | Outperform |
| 2024-01-03 | 개시 | Barclays | Overweight |
| 2023-12-14 | 개시 | Wells Fargo | Equal Weight |
| 2023-03-31 | 개시 | Citigroup | Buy |
| 2023-01-31 | 재개 | Evercore ISI | Outperform |
| 2022-10-11 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-08-22 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-07-11 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-06-07 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-05-26 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-04-12 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-04-01 | 재개 | Credit Suisse | Outperform |
| 2021-03-12 | 재개 | Evercore ISI | In-line |
| 2021-02-04 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-02-02 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2021-01-06 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-01-06 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2020-12-10 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2020-12-03 | 개시 | Mizuho | Neutral |
| 2020-08-06 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-07-15 | 개시 | Barclays | Underweight |
| 2020-06-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-23 | 재개 | Credit Suisse | Outperform |
| 2020-04-16 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-04-13 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-04-01 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-03-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-02-11 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2020-02-07 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-09-12 | 개시 | Deutsche Bank | Hold |
| 2019-07-10 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-04-11 | 개시 | Guggenheim | Buy |
| 2019-04-10 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2019-04-10 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-02-11 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-01-17 | 개시 | UBS | Buy |
| 2018-12-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-10-26 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-09-20 | 개시 | Berenberg | Buy |
| 2018-07-17 | 재개 | Stifel | Hold |
| 2018-04-09 | 개시 | MoffettNathanson | Buy |
| 2018-03-12 | 업그레이드 | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-03-12 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2017-09-25 | 개시 | JP Morgan | Neutral |
| 2017-09-22 | 개시 | William Blair | Outperform |
모두보기
Cencora Inc 주식(COR)의 최신 뉴스
Will Speciality and GLP-1 Drugs Help COR Beat Q2 Earnings Estimates? - TradingView
Those who invested in Cencora (NYSE:COR) five years ago are up 253% - simplywall.st
Unveiling Cencora (COR) Q2 Outlook: Wall Street Estimates for Key Metrics - MSN
Cencora to support US launch of Neurotech’s cell therapy, ENCELTO - Ophthalmology Times
Cencora (COR) Earnings Expected to Grow: Should You Buy? - Yahoo
UBS Adjusts Price Target on Cencora to $335 From $298, Maintains Buy Rating - marketscreener.com
Cencora, Inc. : The resistance should give in - marketscreener.com
Earnings Preview: What To Expect From Cencora's Report - MSN
Cencora (COR) Surged on Strong Returns - Insider Monkey
Cencora executive chairman Steven Collis sells $4.1 million in stock By Investing.com - Investing.com South Africa
Cencora executive chairman Steven Collis sells $4.1 million in stock - Investing.com
Healthcare Cold Chain Logistics Market Report 2025-2035 | High Costs of Cold Storage and Transportation Pose Challenges for Healthcare Logistics - GlobeNewswire Inc.
Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Lobbying Update: $60,000 of CENCORA INC. lobbying was just disclosed - Nasdaq
Will Cencora (COR) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Why Cencora (COR) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Jim Cramer: Cencora (COR) Is a “Must-Own” Drug Middleman – Even If It Should Be Digitized Away - Insider Monkey
TD Cowen Adjusts Price Target on Cencora to $335 From $288, Keeps Buy Rating - marketscreener.com
Baird Adjusts Price Target on Cencora to $314 From $308, Keeps Outperform Rating - marketscreener.com
Jim Cramer is Bullish on These 10 Stocks - Insider Monkey
Morgan Stanley Adjusts Cencora Price Target to $288 From $263, Maintains Equal Weight Rating - MarketScreener
Morgan Stanley Increases Price Target for Cencora (COR) to $288 - GuruFocus
Jim Cramer Likes Cencora (COR) “Middlemen Always Work.” - Insider Monkey
Cencora to Announce Q2 Fiscal 2025 Results on May 7 - MSN
Jim Cramer Discussed These 12 Stocks - Insider Monkey
Here's Why You Should Add Cencora Stock to Your Portfolio Now - MSN
Cencora, Inc. (COR): A Bull Case Theory - MSN
Mizuho raises Cencora stock price target to $305, maintains outperform By Investing.com - Investing.com Canada
Evercore ISI Adjusts Price Target on Cencora to $320 From $280, Maintains Outperform Rating - marketscreener.com
Top 3 MedTech Stocks to Weather the Trump Tariff Turbulence - TradingView
Mizuho raises Cencora stock price target to $305, maintains outperform - Investing.com Australia
These 5 S&P 500 Winners Held Strong In Q1 — Can The Rally Continue? - Benzinga
Why We're Not Concerned About Cencora, Inc.'s (NYSE:COR) Share Price - simplywall.st
4 Low-Beta Healthcare Stocks to Beat Trump's Tariff Blues - TradingView
Has Cencora, Inc. (COR) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Leerink Partners Adjusts Price Target on Cencora to $317 From $301, Maintains Outperform Rating - MarketScreener
Insiders At Cencora Sold US$16m In Stock, Alluding To Potential Weakness - Yahoo Finance
Cencora (COR) is a Top-Ranked Growth Stock: Should You Buy? - Yahoo Finance
Jim Cramer on Cencora (COR): “Smart Moves in the Drug Middleman Game!” - Insider Monkey
Jim Cramer Looked At These 23 Stocks Recently - Insider Monkey
Cencora Inc (COR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.65%
0.20%
자본화:
|
볼륨(24시간):